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A B S T R A C T
Methadone is used for medication-assisted treatment of heroin addiction during pregnancy. The neurodeve-
lopmental outcome of children with prenatal methadone exposure can be sub-optimal. We tested the hypothesis
that brain development is altered among newborn infants whose mothers were prescribed methadone.
20 methadone-exposed neonates born after 37 weeks' postmenstrual age (PMA) and 20 non-exposed controls
underwent diffusion MRI at mean PMA of 39+2 and 41+1 weeks, respectively. An age-optimized Tract-based
Spatial Statistics (TBSS) pipeline was used to perform voxel-wise statistical comparison of fractional anisotropy
(FA) data between exposed and non-exposed neonates.
Methadone-exposed neonates had decreased FA within the centrum semiovale, inferior longitudinal fasciculi
(ILF) and the internal and external capsules after adjustment for GA at MRI (p < 0.05, TFCE corrected). Median
FA across the white matter skeleton was 12% lower among methadone-exposed infants. Mean head cir-
cumference (HC) z-scores were lower in the methadone-exposed group (−0.52 (0.99) vs 1.15 (0.84),
p < 0.001); after adjustment for HC z-scores, differences in FA remained in the anterior and posterior limbs of
the internal capsule and the ILF. Polydrug use among cases was common.
Prenatal methadone exposure is associated with microstructural alteration in major white matter tracts,
which is present at birth and is independent of head growth. Although the findings cannot be attributed to
methadone per se, the data indicate that further research to determine optimal management of opioid use dis-
order during pregnancy is required. Future studies should evaluate childhood outcomes including infant brain
development and long-term neurocognitive function.
1. Introduction
Globally, in 2015 there were estimated to be 17.7million past-year
users of heroin or opium, and increased heroin use is a major driver of
the current opioid epidemic (World Drug Report, 2017). Pregnant
women with opioid use disorder (OUD) due to heroin are recommended
medication-assisted treatment (MAT) with an alternative opioid
(usually methadone or buprenorphine) because treatment is associated
with improved use of antenatal services, reduced use of heroin during
pregnancy and reduced preterm delivery. Fetal benefits of MAT include
improved growth and lower risk of intrauterine death (American
College of Obstetricians and Gynecologists, 2017).
Methadone is a synthetic long acting μ-opioid agonist, which crosses
the placenta freely, thereby exposing the developing fetus to exogenous
opioid at a critical period of brain development. Pre-clinical studies
suggest that prenatal methadone exposure may modify developing
dopaminergic, cholinergic and serotonergic systems, and alter myeli-
nation. Antenatal exposure to the drug has behavioral consequences
including depression, anxiety, and impaired learning, memory and so-
cial function (Chen et al., 2015; Robinson et al., 1996; Vestal-Laborde
et al., 2014; Wong et al., 2014). In humans, prenatal methadone ex-
posure is associated with increased incidence and severity of neonatal
abstinence syndrome (NAS) (Wilson et al., 1981; Zelson et al., 1973)
compared with heroin exposure, and with altered visual maturation in
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childhood (McGlone et al., 2013a; McGlone et al., 2008; Whitham et al.,
2010). These observations raise the possibility that prenatal methadone
exposure may modify early brain development; however, the possible
role of confounding by postnatal events, including pharmacotherapy
with opioid for NAS and environmental factors, leaves uncertainty
about the impact of prenatal methadone exposure on the developing
brain.
Diffusion MRI (dMRI) is an established technique for studying brain
development in early life. It provides objective measures of white
matter microstructure that are sensitive to atypical developmental and
injurious processes in the perinatal period, and which correlate with
neurodevelopmental outcome in childhood (Counsell et al., 2014).
Specifically, fractional anisotropy (FA) is a voxel-wise measure of the
directional dependence of water molecule diffusion in tissue which is
influenced by fiber density, axonal diameter and myelination, thereby
enabling inference about underlying tissue microstructure. Tract-based
Spatial Statistics (TBSS) enables unbiased group-wise analysis of FA
volumes derived from dMRI data (Ball et al., 2010; Smith et al., 2006).
It has been applied to neonatal dMRI to map microstructural change in
white matter tracts of preterm infants at term equivalent age (Anjari
et al., 2007), to identify clinical risk factors for altered brain develop-
ment (Anblagan et al., 2016; Ball et al., 2010; Boardman et al., 2014),
and to investigate neuroprotective treatment strategies in randomized
clinical trials (Azzopardi et al., 2016; O'Gorman et al., 2015; Porter
et al., 2010).
Based on the harmful effects of prenatal methadone exposure on
neural systems and abnormal behavioral outcomes in pre-clinical
models; and on human studies which suggest a modifying effect of
prenatal methadone on postnatal behavior and development, we hy-
pothesized that white matter development of neonates would be altered
in neonates exposed to methadone in utero. We used TBSS to examine
risks associated with prenatal methadone exposure, while minimizing
the role of confounding by postnatal events and drug exposures.
2. Methods and materials
2.1. Participants
The study was conducted according to the principles of the
Declaration of Helsinki and ethical approval was obtained from the UK
National Ethics Service (South East Scotland Research Ethics
Committee 02, 14/SS/1106). Written informed parental consent was
obtained for all participants. The study group consisted of infants>
37 weeks' postmenstrual age (PMA) whose mothers had been pre-
scribed methadone during pregnancy for the treatment of OUD (cases)
and a comparator group of healthy infants born at> 37 weeks' PMA
whose mothers did not use opioids (controls).
Mothers of cases were identified through a specialist antenatal clinic
for pregnant women with substance misuse. All cases were born at the
Royal Infirmary of Edinburgh between February 2015 and April 2017
and underwent MRI brain scanning at the Clinical Research Imaging
Centre, University of Edinburgh. The controls were selected, based on
age matching, from a previously described group of healthy term neo-
nates recruited as part of a study of typical brain development (Blesa
et al., 2016) (South East Scotland Research Ethics Committee 02, 13/
SS/0143). For cases and controls, exclusion criteria were congenital
infection or chromosomal abnormalities, or any implanted medical
device.
Clinical and demographic information was extracted from the mo-
ther and infant clinical records. Birth weight and head circumference
(HC) were described in terms of z-score for week of gestational age,
calculated using INTERGROWTH-21st reference standards (Villar et al.,
2014). The Scottish Index of Multiple Deprivation (SIMD) was used to
characterize deprivation. The SIMD is the official Government tool used
to identify areas of deprivation: it divides Scotland into around 6505
areas each containing around 350 households and assigns an index to
each area based on multiple measures of deprivation. The data are
ranked from most to least deprived and are presented as deciles.
2.2. Ascertainment of maternal drug use
Details of methadone use, tobacco smoking, alcohol intake, and use
of non-prescribed drugs were ascertained from medical records (in-
cluding prescription charts), biological screening samples when these
were performed as part of clinical care, and maternal interview at the
time of delivery (V.M.)
2.3. MRI acquisition
MRI was performed on a Siemens Magnetom Verio 3T system
(Siemens Healthcare Gmbh, Erlangen, Germany) using a 12-channel
matrix phased array head coil. All infants were scanned axially to ac-
quire: 3D T1-weighted MPRAGE volume (1 mm3 resolution), T2-
weighted STIR (0.9 mm3 resolution), T2-weighted FLAIR (1 mm3 re-
solution), and diffusion MRI (dMRI) (11 T2- and 64 diffusion encoding
direction (b = 750 s/mm2) single-shot spin-echo echo planar imaging
(EPI) volumes with 2 mm isotropic voxels, TE = 106 ms and
TR = 7300 ms. Images were reported by a pediatric radiologist with
experience in neonatal MRI (AQ), according to the system described by
Woodward et al. (Woodward et al., 2006), with the modification for
grey matter scores proposed by Leuchter et al. (Leuchter et al., 2014).
MRI was performed in the neonatal period during natural sleep,
without sedation. A neonatologist was present for the duration of each
MRI scan, and the infant had continuous oxygen saturation and heart
rate monitoring. For acoustic protection, flexible earplugs and neonatal
earmuffs (MiniMuffs, Nat's Medical Inc., CA) were used.
2.4. Tract-based spatial statistics
DMRI data were preprocessed using FSL tools (FMRIB, Oxford, UK;
http://www.ndcn.ox.ac.uk/divisions/fmrib). This included brain ex-
traction, and removal of bulk infant motion and eddy current induced
artefacts by registering the diffusion-weighted volumes to the first T2-
weighted EPI volume for each subject. Using DTIFIT, FA volumes were
generated for every subject. Diffusion volumes were assessed visually
and were excluded if there was motion corruption.
TBSS analysis was performed using a pipeline optimized for neo-
natal dMRI data (Ball et al., 2010). An average FA volume and mean FA
skeleton (thresholded at FA > 0.15) were created from the aligned
data. Statistical comparison between groups with and without exposure
to methadone during pregnancy was performed with FSL's Randomise
using a general linear univariate model, with GA at image acquisition
and HC z-score at image acquisition listed as covariates. All FA data
were subject to family-wise error correction for multiple comparisons
following threshold-free cluster enhancement (TFCE) and are shown at
p < 0.05 (Smith and Nichols, 2009).
2.5. Statistics
Student's t-test or the Mann-Whitney test was used to investigate
differences in clinical and demographic variables between infants ex-
posed to methadone (n = 20) and those not exposed (n = 20) and chi-
squared or Fisher's exact test was used to compare proportions.
Statistical analysis was performed using SPSS v22.0 (SPSS Inc.,
Chicago, IL).
3. Results
3.1. Participants
Conventional structural and dMRI data amenable to TBSS analysis
were acquired from 40 neonates: 20 cases (10 female), who were
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exposed to prenatal methadone, and 20 unexposed controls (7 female).
Table 1 summarizes maternal and infant characteristics.
The mean methadone dose prescribed at pregnancy booking was
55 mg/day (range 0–160) and the mean dose at delivery was 70 mg/
day (range 8–160). Nineteen (95%) of the women prescribed metha-
done smoked tobacco, one reported drinking excessive alcohol (4 units/
day at booking), and nineteen women had illicit or prescribed polydrug
use (Fig. 1). Additional prescribed medications included paroxetine
(n = 1), mirtazapine (n = 1), gabapentin (n = 2), and pregabalin
(n = 1).
None of the cases had neonatal encephalopathy, seizures or hy-
poglycemia. The mean arterial cord pH of the group was 7.26 (range
7.16–7.36). Three cases had minor congenital anomalies (1 hypospa-
dias, 1 cleft lip, 1 fixed bilateral talipes). One methadone exposed infant
required admission to the Neonatal Unit for treatment of transient ta-
chypnoea of the newborn.
No infant had received pharmacological treatment for NAS at the
time of image acquisition and none of the control group was exposed
prenatally to opioid drugs.
3.2. Magnetic Resonance Imaging
None of the cases or controls had features consistent with injury to
white matter or grey matter on conventional structural T1- or T2-
weighted structural MRI. Four cases had mild enlargement of the lateral
ventricular system; 1 case had asymmetric myelination of the posterior
limb of the internal capsule (but had developed symmetric myelination
on repeat MRI four weeks later); and no case had abnormalities in
brainstem, cerebellum, deep or cortical grey matter, or extracerebral
space. Two (10%) methadone exposed infants had developmental ve-
nous anomalies: one consisted of an area of low T2-weighted signal in
the left peritrigonal white matter (most likely haemosiderin), with a
curvilinear vessel extending peripherally and draining into the superior
anastamotic vein of Trolland, which continues up to the superior sa-
gittal sinus; and the second was characterized by an area of low T2-
weighted signal in the right peritrigonal white matter with a low T2-
weighted signal vessel that drains toward the choroid plexus.
3.3. White matter correlates of prenatal methadone exposure
Methadone-exposed neonates had decreased FA within the centrum
semiovale, inferior longitudinal fasciculi (ILF), and the internal and
external capsules after adjustment for PMA at MRI (p < 0.05, TCFE
corrected) (Fig. 2A). Mean HC z-scores were lower in the methadone
exposed group (−0.52 (0.99) vs 1.15 (0.84), p < 0.001). After ad-
justment for HC z-scores, differences in FA remained in the anterior and
posterior limbs of the internal capsule and the ILF (Fig. 2B). Radial
diffusivity was increased in internal capsule and inferior longitudinal
fasciculus in neonates with prenatal methadone exposure (Fig. 3).
There were no differences in mean or axial diffusivities between groups.
Median FA across the white matter skeleton was 12% lower among
methadone-exposed infants (Fig. 4).
4. Discussion
These data show that prenatal exposure to methadone is associated
with altered microstructure in major white matter tracts of the newborn
brain, independent of head growth. Children whose mothers take me-
thadone during pregnancy are at increased risk of neurodevelopmental
impairment, behavioral difficulties, and visual problems, but study
designs have left uncertainty about the role of confounding by pre-
maturity, postnatal opioid exposure for treatment of NAS, and en-
vironmental factors, in mediating adverse outcomes(Hans and Jeremy,
2001; Hunt et al., 2008; Konijnenberg and Melinder, 2015; McGlone
et al., 2014; McGlone and Mactier, 2015; Rosen and Johnson, 1985; van
Baar, 1990; Wilson, 1989). An association between prenatal methadone
exposure and reduced somatic and head growth is documented (Mactier
et al., 2014) but to our knowledge, this is first study to demonstrate
brain tissue effects present around the time of birth after methadone
exposure in utero.
We used TBSS to investigate brain development because of its sen-
sitivity to group-wise differences in FA when used to survey the entire
white matter skeleton (Ball et al., 2013). FA is a robust marker of tract
microstructure that reflects fiber density, axonal diameter, wrapping by
pre-myelinating oligodendrocytes and myelination. Therefore, these
data suggest that neonates exposed to methadone in utero have less
coherently organized and more immature fiber tracts compared to
controls. Furthermore, correspondent increases in radial diffusivity
without changes in axial diffusivity imply that abnormal myelination
may contribute to altered FA among the cases. Since neonatal FA values
in major white matter tracts correlate with later neurodevelopment, the
findings may explain the prevalence of neurobehavioral problems seen
in children with prenatal methadone exposure.
Quantitative MRI techniques have identified specific vulnerabilities
of the developing brain to psychoactive drugs. Midazolam exposure
during neonatal intensive care of preterm infants is associated with
attenuated hippocampal growth (Duerden et al., 2016), and functional
connectivity of the amygdala–frontal and thalamic networks is altered
in neonates with prenatal cocaine exposure (Salzwedel et al., 2016;
Table 1
Maternal and infant characteristics of participants. BMI, body mass index; SIMD, Scottish
Index of Multiple Deprivation; PMA, postmenstrual age; HC, head circumference.
Methadone Control p value
n = 20 n = 20
Maternal characteristics
Mean age (range)/years 30 (23–41) 30.9 (19–39) 0.56
Mean BMI (range) 25.8 (21–41) 23.2 (19–39) 0.08
Median SIMD decile
(Interquartile range)
3 (2–5) 8 (6–10) 0.012
Infant characteristics
Mean PMA at birth (range)/
weeks
38+5
(37+1–41+0)
39+1
(37+2–41+3)
0.32
Gender (M:F) 10:10 13:7 0.52
Mean birth weight (range)/g 2721
(2150–3440)
3349
(2346–4550)
< 0.01
Mean birth weight z-score
(sd)
−1.062 (0.68) 0.443 (0.86) < 0.01
Median (range) postnatal age
at scan/days
3 (1 to 21) 13 (5 to 29) 0.005
Mean PMA at scan (range)/
weeks
39+2
(37+2–41+4)
41+1
(39+0–42+2)
0.004
Mean HC at scan (range)/cm 33.1 (31.2–35.0) 35.9 (32.6–37.4) < 0.01
Mean HC z-score (sd) −0.523 (0.986) 1.146 (0.837) < 0.01
Fig. 1. Euler diagram indicating prenatal drug exposures. Stimulant includes cocaine and
amphetamine; *codeine phosphate and tramadol.
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Salzwedel et al., 2015). In a preliminary study, Walhovd and colleagues
reported higher mean diffusivity in the superior longitudinal fasciculus
of 13 methadone-exposed cases compared to 7 controls, but infants
were scanned at mean age of 3 weeks after birth and 85% of the cases
had been treated with morphine for NAS, which limits inference about
the effects of prenatal opioid exposure (Walhovd et al., 2012). Two
(10%) cases had developmental venous anomalies (DVA), which was
higher than expected based on estimated prevalence of 1.5% in neo-
nates (Brinjikji et al., 2017). These did not occur in the cases exposed to
cocaine, which is known to be associated with central nervous system
vascular anomalies (Frank et al., 1999); therefore the possibility that
prenatal methadone exposure is associated with CNS vascular mal-
formation warrants further study.
All of our cases had been exposed to once daily dosing with me-
thadone. Although the benefits of MAT with an opioid substitute during
pregnancy are unequivocal (ACOG, 2017), there is no consensus re-
garding the optimal dosing regimen for methadone, or the role of bu-
prenorphine as an alternative substitute. A single daily dose of me-
thadone is commonly prescribed, but some authors suggest that
accelerated metabolism of methadone by physiological induction of
CYP450 enzymes during pregnancy might predispose women and
fetuses to daily withdrawal stress and risk of relapse to illicit drugs
(Bogen et al., 2013; McCarthy et al., 2017; McCarthy et al., 2015).
Studies that support the use of divided dosing to minimize fluctuations
in serum concentration report favorable effects on maternal symptoms
of withdrawal, and on fetal neurobehavior and NAS prevalence
(Jansson et al., 2009; McCarthy et al., 2015; Wittmann and Segal,
1991), but no study has evaluated the impact of dosing regimen on
fetal/neonatal brain development or long-term outcome. Monitoring of
maternal plasma methadone concentration during the peripartum
period with dose titration to keep levels within the maternal ther-
apeutic range has been suggested, but this is not practiced widely
(McCarthy et al., 2017). Buprenorphine is a partial mu-opioid agonist
and kappa-opioid antagonist that is an acceptable substitute to preg-
nant women and is associated with lower risk of preterm birth, im-
proved growth parameters at birth and less NAS, without apparent
harm, when compared with methadone (Jones et al., 2010; Zedler et al.,
2016). These neonatal outcomes suggest that buprenorphine may have
a more favorable safety profile for the child, although long-term out-
come studies are required.
Polydrug use, both illicit and prescribed, was very common among
women prescribed methadone in our study. This is consistent with
Fig. 2. Mean FA map of the subjects in transverse, coronal and sagittal planes. Voxels with significantly lower FA in neonates with prenatal methadone exposure are shown in yellow-red
color scale. Fig. 2A shows results adjusted for PMA at scan, and Fig. 2B shows results adjusted for PMA at scan and head circumference z-score. FA, fractional anisotropy.
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observations from other cohorts of methadone using pregnant women
(McGlone et al., 2013b; Rosen and Johnson, 1985; van Baar, 1990). In
our study population, heroin and oral benzodiazepines were used by 11
(55%) and 12 (60%) of cases respectively, so it is possible that either
drug could have confounded the observed association. No other drug
class (anti-depressant, anti-epileptic, stimulant) was taken by> 15% of
the cases so it is unlikely that exposure to these classes of drug ex-
plained the findings. The research implication of highly prevalent
polydrug use in the target population is that future studies into optimal
management of OUD in pregnancy are likely to require pragmatic de-
signs that define case definition based on prescribed substitute, with
post hoc adjustment for other drug exposures if they are shown to differ
between groups.
The strengths of the study are that: dMRI acquisition took place
soon after birth before exposure to postnatal opioids or other phar-
macological treatment for NAS; preterm birth, which is an important
source of confounding for neurodevelopmental outcome was excluded;
and detailed information about methadone dose and exposure to other
drugs was available. Our study was limited by reliance on maternal
report for drug exposures among control women; however, none of the
control participants were prescribed opioids during pregnancy, and the
likelihood of undisclosed heroin use or non-prescription opioids was
low. A limitation of this study is that we could not evaluate causation,
and therefore cannot exclude potential mediating or interacting factors
such timing and dose effects of methadone and the role of other pre-
natal drug exposures. However, our data support pre-clinical studies,
objective studies of visuo-cortical function in the newborn period and
later infancy, and neurodevelopmental and behavioral studies, which
strongly suggest an adverse effect of prenatal methadone upon the
developing fetal brain and upon long-term childhood outcomes.
In conclusion, prenatal methadone exposure is associated with al-
tered white matter microstructure that is apparent soon after birth. The
data focus research attention on determining optimal management of
pregnant women with OUD, including a pressing need to evaluate
methadone dose regimens and alternative substitutes; future study de-
signs should evaluate fetal or neonatal brain development and long-
term neurocognitive outcome.
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Fig. 3. Mean RD map of the subjects in transverse, coronal and sagittal planes. Voxels with significantly higher RD in neonates with prenatal methadone exposure are shown in yellow-red
colour scale. Fig. 3A shows results adjusted for PMA at scan, and Fig. 3B shows results adjusted for PMA at scan and head circumference z-score. RD, radial diffusivity.
Fig. 4. Mean FA across the white matter skeleton of neonates with prenatal methadone
exposure compared with unexposed controls. FA, fractional anisotropy.
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